CSTL
Castle Biosciences Inc - 2024 Revenue Expected to Exceed $320-330 Million, 50% Growth Over 2023
时间:2025-01-13 07:00:34 市场: 美股 综合
Castle Biosciences Inc: New York State Department of Health Approval of Its Tissuecypher Barrett's Esophagus Test
时间:2025-01-06 20:04:22 市场: 美股 综合
Castle Biosciences Inc: Expects to Launch Pipeline Test by End of 2025
时间:2024-12-23 20:06:58 市场: 美股 综合
Castle Biosciences Highlights Progress for Its Pipeline Atopic Dermatitis Gene Expression Profile Test
时间:2024-12-23 20:06:58 市场: 美股 综合
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
时间:2024-12-19 20:00:00 市场: 美股 综合
Castle Biosciences Inc : Scotiabank Raises Target Price to $44 From $37
时间:2024-11-05 22:09:49 市场: 美股 综合
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
时间:2024-09-16 19:00:02 市场: 美股 综合